Company intelligence / Profile preview

Soma Biotech

Granada, Andalusia, Spain

Ownership: Private
Development stage: Other

Overview

Soma Biotech is a preclinical-stage biotechnology company focused on developing the next generation of CAR-T cell therapies for solid tumors. Their lead research involves targeting GRP78 (HSPA5), a stress-induced protein overexpressed on the surface of various cancer cells, specifically for the treatment of glioblastoma.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

University of GranadaAndalusian Network for the Design and Translation of Advanced Therapies (ANd&A)

Beyond the preview

Go deeper on Soma Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Soma Biotech.

Explore the full profile